Talphera, Inc. (NASDAQ:TLPH) Chief Medical Officer Aslam Shakil completed a personal purchase of 35,000 shares of the company's common stock on February 12, 2026, at a per-share price of $0.8123, for a total outlay of $28,430, according to a Form 4 submitted to the Securities and Exchange Commission. Following the transaction, Shakil's direct ownership in Talphera rose to 83,178 shares, as reported in the filing.
The filing also records a contemporaneous grant: Shakil was awarded an option to acquire 205,000 shares of common stock with an exercise price of $0.8123 per share. The option carries a tenure through February 11, 2036. Vesting for the option is structured so that one fourth of the option shares vest on the one-year anniversary of the grant date, with the remaining shares vesting in 36 equal monthly installments thereafter until fully vested.
Market context included in the filing notes that Talphera shares were trading at $0.78 at the time the report was prepared. That trading level represents a decline of roughly 32% year-to-date, while the stock has advanced nearly 60% over the prior six months. The filing cites InvestingPro analysis, which states the stock appears undervalued at current levels and lists analyst price targets in a range from $3.00 to $3.50.
Investors seeking additional detail on the company's financial metrics and prospects are directed in the filing to a Pro Research Report that covers Talphera and more than 1,400 other U.S. equities on InvestingPro.
Transaction specifics
- Purchase: 35,000 shares at $0.8123 per share on February 12, 2026; total cost $28,430.
- Post-purchase ownership: Direct holdings increased to 83,178 shares.
- Option grant: 205,000 shares exercisable at $0.8123 per share, expiration February 11, 2036.
- Vesting: 25% after one year, remainder vests in 36 equal monthly installments.
The SEC Form 4 provides the formal record of both the cash purchase and the option award. The filing includes the InvestingPro commentary on valuation and the analyst target range between $3.00 and $3.50, but does not provide additional company statements or projections within the filing itself.